Latest news from OncoSec Medical, Inc. on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/novel-approaches-to-immunotherapy-rapidly-gaining-ground/?sc=rsin /articles/novel-approaches-to-immunotherapy-rapidly-gaining-ground/?sc=rsin Fri, 05 Sep 2014 08:45:00 EST Expert is available to comment on the impending likely approval of Merck & Co.'s immuno-oncology drug, pembrolizumab, as a treatment for melanoma. According to Dr. Robert H. Pierce of OncoSec Medical, it is believed that 60 to 70 percent of patients with metastatic melanoma exhibit no response to anti-PD-1 immunotherapy that Merck is developing, so it could be useful to combine it with other forms of immunotherapy. One such alternate form is OncoSec's ImmunoPulse, which delivers brief electrical pulses of DNA IL-12 and has shown in early studies to date to penetrate and destroy cancer cells. OncoSec Medical, Inc. /articles/for-metastatic-melanoma-patients-new-approach-to-treatment-may-be-on-horizon/?sc=rsin /articles/for-metastatic-melanoma-patients-new-approach-to-treatment-may-be-on-horizon/?sc=rsin Fri, 16 Nov 2012 09:30:00 EST At a recent scientific meeting (the 6th World Meeting of Interdisciplinary Melanoma/Skin Care Centres & 8th EADO Congress), OncoSec announced positive results from an ongoing trial investigating its own proprietary treatment in metastatic melanoma patients. OncoSec Medical, Inc. /articles/skin-cancer-awareness-with-melanoma-rising-among-young-adults-new-treatments-could-play-a-key-role/?sc=rsin /articles/skin-cancer-awareness-with-melanoma-rising-among-young-adults-new-treatments-could-play-a-key-role/?sc=rsin Tue, 15 May 2012 09:00:00 EST As the U.S. observes Skin Cancer Awareness Month in May, a report has some sobering news for young adults: The incidence of melanoma increased eightfold among young women and fourfold among young men from 1970 through 2009. During Skin Cancer Awareness Month, we encourage those suffering from melanoma and other forms of skin cancer to talk to a doctor about the possibility of enrolling in a nearby clinical trial. OncoSec Medical, Inc.